Physician profile
Michael J Eldemire
NPI 1770548430
$8,527.15
in general payments reported to CMS, 2019-2025
61 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,726 · 2020: $655 · 2021: $295 · 2022: $984 · 2023: $1,379 · 2024: $1,978 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,867.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $966.49 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $513.43 | 2022-2025 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $500.45 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $445.96 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Vanda Pharmaceuticals INC. | $431.28 | 2022-2025 | Hetlioz, Fanapt |
| Novartis Pharmaceuticals Corporation | $380.12 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $375.05 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.53 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $324.38 | 2020-2025 | |
| Lilly USA, LLC | $278.30 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $270.65 | 2019-2023 | Otezla, Repatha |
| Ucb, INC. | $259.69 | 2019-2025 | Briviact |
| Janssen Pharmaceuticals, INC | $257.45 | 2019-2024 | Spravato, Xarelto |
| Exact Sciences Corporation | $244.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $222.66 | 2022-2025 | Caplyta |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Eldemire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.